Supio
Reads entire plaintiff case files and drafts the paperwork mass-tort firms bill hours for
Overview
Supio is agentic AI built specifically for plaintiff personal-injury and mass-tort law firms — it ingests medical records and case files to produce chronologies, demand letters, and case valuations with source citations, integrated into Litify, MyCase, and CasePeer.
What you can produce with Supio
- Automated medical chronology generation
- AI-drafted demand letters
- Case valuation / case-economics ledger
- Litigation drafting with page-level source citations
- Integrations with Litify, MyCase, CasePeer
- SOC 2 Type II, HIPAA, GDPR compliance
- Trial transcript analysis
ASEAN Perspective
Supio in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Supio picked one of the most document-heavy corners of law — plaintiff PI and mass tort — and built specifically for it, rather than trying to be general-purpose legal AI. Medical chronologies and demand letters are exactly the grinding, citation-heavy work agentic document analysis is good at, and Thomson Reuters took a strategic stake and struck a Westlaw partnership, which is a meaningful vote of confidence from inside the legal-tech establishment.
The headline numbers — a $24M jury award after using Supio to analyze trial transcripts, a firm going from a $95,000 to $400,000 settlement — are vendor-supplied case studies, not independent verification, so treat them as directional rather than typical. Pricing isn't published anywhere; firms only get real numbers after a sales call, priced by case volume. It's a strong fit if your firm lives in Litify, MyCase, or CasePeer and drowns in medical records — narrower than that, it's not built for you.
What people say
Supio was founded in San Francisco around 2021 by Jerry Zhou and Kyle Lam, both ex-Microsoft, and has since raised roughly $91M — a $25M Series A in August 2024 and a $60M Series B in April 2025 led by Sapphire Ventures, with Thomson Reuters Ventures also participating. The company says ARR quadrupled between those two rounds.
The product reads full case files — medical records, bills, flow sheets, depositions — and generates medical chronologies, demand letters, case-economics ledgers, and litigation drafts, each with page-level citations back to the source document. It integrates with plaintiff-side practice management systems Litify, MyCase, and CasePeer, and carries SOC 2 Type II, HIPAA, and GDPR compliance certifications, which matters given the sensitive medical records it processes.
Supio doesn't have a significant public presence on G2 or Capterra the way horizontal SaaS tools do, which is typical for enterprise legal software sold through direct sales rather than self-serve signup. Independent aggregator AI Agent Square scores it 8.1/10 and calls it the most complete AI platform in its specific plaintiff/mass-tort niche. The company's own case studies cite an Oregon attorney using Supio's transcript analysis in real time during trial to help secure a $24 million jury award, and another firm reporting a settlement jump from $95,000 to $400,000 after using the platform's case valuation tools — outcomes that are vendor-reported and worth treating with appropriate skepticism given no independent firm has verified the causal link.
Supio has processed more than 27,000 cases and its customers reportedly generated over $1 billion in settlements in the past year, according to the company. A newer Supio Agent product extends beyond document review into running parts of a firm's case operations rather than just analyzing files. Pricing is not published; the company sells by case volume through a direct sales process, standard for this tier of legal software but a barrier for smaller firms wanting to compare costs without a demo call.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Supio's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Supio unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Supio directly →
Spotted something out of date? Suggest an update →
More in Business & Finance
